8,657 Shares in Amgen Inc. $AMGN Purchased by Flagship Capital Management Inc.

Key Points

• Flagship Capital Management opened a new position in Amgen, acquiring 8,657 shares (~$2.83M) in Q4, which represents about 2.0% of the firm's holdings and makes AMGN its 16th-largest position; institutional investors own roughly 76.5% of the stock.
• Amgen topped expectations with $5.29 EPS (vs. $4.76 est.) and $9.87B revenue, set FY2026 guidance of 21.60–23.00 EPS, announced a quarterly dividend of $2.52 (2.8% yield), and carries an analyst consensus of "Hold" with a $355.16 target.

Flagship Capital Management Inc. acquired a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 8,657 shares of the medical research company's stock, valued at approximately $2,834,000. Amgen makes up approximately 2.0% of Flagship Capital Management Inc.'s holdings, making the stock its 16th biggest position.

Other large investors also recently bought and sold shares of the company. Sequoia Financial Advisors LLC increased its position in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company's stock valued at $45,334,000 after purchasing an additional 3,619 shares during the last quarter. Davis Capital Management purchased a new stake in shares of Amgen during the 3rd quarter valued at about $1,841,000. D.A. Davidson & CO. increased its position in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company's stock valued at $68,590,000 after purchasing an additional 6,222 shares during the last quarter. Global Wealth Management Investment Advisory Inc. increased its position in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company's stock valued at $3,684,000 after purchasing an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of Amgen by 18.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company's stock valued at $10,888,000 after purchasing an additional 6,115 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. TD Cowen reiterated a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Leerink Partners reiterated a "market perform" rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a research note on Wednesday, February 4th. Rothschild & Co Redburn boosted their price objective on Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a research note on Wednesday, February 18th. Finally, Truist Financial boosted their price objective on Amgen from $318.00 to $319.00 and gave the company a "hold" rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $355.16.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 data for a subcutaneous/on‑body TEPEZZA injector showed strong efficacy and safety vs IV, potentially enabling at‑home dosing and broader use for Thyroid Eye Disease — this could expand TEPEZZA’s addressable market and improve convenience-driven uptake. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Royal Bank of Canada lifted its price target to $370, a bullish signal that supports upside versus prior analyst levels and may underpin buying interest. Royal Bank Of Canada Increases Amgen Price Target to $370
• Positive Sentiment: Investors continue to focus on Amgen’s push into GLP‑1/obesity (MariTide — move to a once‑quarterly injectable was highlighted), which positions the company in a high‑growth segment and complements its existing biologics portfolio. We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play.
• Neutral Sentiment: Analysts/market pieces note recent share gains and market outperformance, reflecting broader healthcare strength and momentum rather than company‑specific catalysts alone. Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: Guggenheim and Cantor Fitzgerald have maintained/reaffirmed neutral ratings ($351 and $350 targets respectively), signaling limited near‑term upside from their perspectives and keeping sentiment mixed. Guggenheim Adjusts Amgen Price Target Cantor Fitzgerald Reaffirms Neutral
• Negative Sentiment: Morgan Stanley kept a Hold and a $309 target, highlighting limited near‑term upside and providing a counterweight to bullish notes — this could pressure sentiment if investors focus on valuation gaps. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
• Negative Sentiment: Competitive pressure from Eli Lilly (and other GLP‑1 leaders) and debates over IMID positioning remain a risk to market share and pricing power in obesity/immunology categories. Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs

Amgen Trading Up 1.7%

AMGN stock opened at $355.60 on Friday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $191.91 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 3.47 and a beta of 0.47. The business has a 50 day simple moving average of $363.69 and a two-hundred day simple moving average of $334.30.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the company posted $5.31 EPS. The firm's revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio is 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.